Loading stock data…
Incannex Healthcare Inc (IXHL)
$3.37+0.13 (+3.85%)
Market ClosedLast close Sep 8
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Incannex Healthcare Inc. in the Healthcare sector is trading at $3.37 with a market capitalization of $44M. Wall Street consensus targets $18.37 (1 analysts), implying a +445.2% move over the next 12 months. The stock is currently near its 52-week low of $2.49, remaining 42.4% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +445.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | — | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.97M↑ | -$6.51M↓ | -$6.41M | — | -$4.58M |
| Net Income | -$3.88M↑ | -$6.52M↓ | -$6.41M↑ | -$7.48M↓ | -$3.97M |
Peer Comparison
JNJUNHPFE
Fundamentals
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose com...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$43.67M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-22.34%
Volume
Today's trading volume
48,059
Recent News
Incannex (IXHL) Secures U.S. Patent Grant in Obstructive Sleep Apnea for IHL-42X
Incannex Healthcare Inc. (NASDAQ:IXHL) is one of the best strong buy penny stocks to invest in now. Incannex Healthcare Inc. (NASDAQ:IXHL) announced on June 25 the granting of a key patent by the United States Patent and Trademark Office (USPTO) titled “Compositions and Methods of Treatment for Obstructive Sleep Apnea.” Management stated that the granted patent […]
Incannex Healthcare Inc. (IXHL) Implements 1-for-30 Reverse Split Effective February 26
Incannex Healthcare Inc. (NASDAQ:IXHL) is among the 11 Best Pot Stocks to Buy According to Hedge Funds. On February 25, Incannex Healthcare Inc. (NASDAQ:IXHL) announced that its board of directors approved a 1-for-30 reverse stock split of the company’s common stock. The reverse split had previously been approved by stockholders at a special meeting held […]
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Tilray Rebranded Italian Medical Cannabis Arm as Tilray Medical Italia Aurora Cannabis Won EU-wide Protection for its Farm Gas and Sourdough Cannabis Varieties Simply Solventless Sharpened Growth Strategy with Uncommon Cannabis Acquisition and Humble Retrofit Progress Key Takeaways; Psychedelic Sector Definium Therapeutics Launched ‘Rerouting Minds’ Campaign to Spotlight the Science Behind […]
What Makes Incannex Healthcare Inc. (IXHL) a New Buy Stock
Incannex Healthcare Inc. (IXHL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.